

Pharmacy and Therapeutics Committee Meeting
June 14th, 2021
Agenda

I. Review and Approval of Minutes – March 29th, 2021 meeting

II. Pharmacy/Formulary/Lab/AIC

a. Biosimilar discussion continued

Avsola© biosimilar Remicade© - preferred status for Cigna Commercial plans as of July 1.

Nivestym© (filgrastim-aafi) – Pfizer- biosimilar Neupogen© - preferred status for Cigna commercial, July 1

Inflectra© (infliximab-dyyb) – Pfizer - biosimilar Remicade© - preferred status for Anthem BCBS commercial, July 1

b. New drugs

i. Fotiva© (Tivozanib)

ii. Zylonta© (loncastuximab-tesirine-lpyl)

iii. Jemperil© (dostarlimab-gxly)

iv. Brukinsa© (zanubrutinib)

c. New indications/ Label updates

- Trodelvy© (sacituximab govitecan)
- Keytruda© (pembrolizumab) Gastric GEJ
- Keytrud© (pembrolizumab) Her2+ Gastric, GEJ
- Opdivo© (nivolumab)
- Erbitux© (cetuximab) dosing
- Sarelisa© (Isatuximab-irfe) MM

III. Lab/Pharmacy/Clinical

a. Removal of mannitol from Cisplatin protocols - old

Discussion

b. Drug shortages

Chris

c. Consent form for injectable iron

Shirlinda

d. Antiemetics/ New payer policy – UHC July 1st

Alok

IV. Retail

Oral Adherence template

Chris

V. Next meeting dates (August 16th)

Alok